In the present study, we demonstrated that eNOS exhibited a significant increased expression in high-grade prostate cancer, and also metastatic CRPC, further confirming our previous findings showing its upregulation in CRPC tissues and also an antiandrogen-resistant cell line model [27]. The gene discussed is NOS3; the disease is prostate cancer.